Prime View The 10 Most Emerging Startups of 2018 | Page 18

ASVINS LIFETECHNOLOGIES
Offers World-class Solution in Molecular Diagnostics and Life Sciences
Asvins Lifetechnologies was incorporated in the year 2016 with a vision to enable molecular diagnostics and
life sciences solutions on a centralized basis in India. The company is a part of the prestigious 60 year old
NSP group having diversified interests in Life sciences, Healthcare diagnostics and Blood Banking solutions.
World-class Products and Services
SAGAR MARWAHA
Director
Asvins has collaborated with one of the leading Molecular Dx
company named Biocartis, NV, based in Belgium to get their
fastest fully automated Molecular Diagnostics platform named
Idylla to the Indian market and accessible to the physicians for
early diagnosis less than 3 hours .Idylla, fully automated, real-time
Polymerase Chain Reaction (PCR) based molecular diagnostics
system, is designed to offer physicians fast access to highly
reliable clinical molecular diagnostic information, anywhere
and anytime. Idylla™ detects and quantifies multiple DNA or
RNA-based biomarkers in a wide variety of patient sample types.
Asvins targeted audience would be Corporate/Private Cancer
Hospitals, Super Speciality Hospitals,
Government/Semi-Government Medical institutions focussing
on cancer care, Corporate/Private Diagnostic service providers,
Pharma companies who are providing various drugs for cancer
treatment.
Some of the incredible achievements of Asvins Lifetechnologies
is, it has been listed by Silicone India magazine as TOP 10
Lifesciences Startup in India and awarded for best Customer
Relationship by Biocartis N.V.
Current Scenario of Cancer Disease in India
The most critical issue India is facing is the rate of mortality due to cancer. The value touched an alarming
limit of 806000 cases in the last century. Cancer is the second most common disease in India responsible for
maximum mortality with about 0.3 million deaths per year. Besides, attempts have been made to describe the
main causes of cancer along with their preventive measures. In addition to this, efforts have also been made
to predict the effect of increasing number of cancer patients on the Indian economy. In low and middle-in-
come countries, limited access to affordable and quality cancer diagnosis and treatment has contributed to
mortality-to-incidence ratios approximately 20% higher than those of industrialized countries.
Company’s Motive is to Overcome the Issues Related to Higher Cost and
Turn-around Time
The spending on healthcare is invariably growing faster than the GDP. The rate of growth of healthcare
expenditure has exceeded that of GDP. Macroeconomic factors like aging population or insufficient public
funding are challenging to both receivers and providers of healthcare. These advanced, automated and
integrated technologies widen the application scope of molecular diagnostics, they also lead to high test
costs, which are unaffordable to huge sections of patients in India. Besides, lack of healthcare insurance and
reimbursement schemes for diagnostics, which usually are not considered as important as drugs, further
limits adoption in the region.
18